PDF herunterladen
Thromb Haemost 2018; 118(09): 1556-1563
DOI: 10.1055/s-0038-1668522
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Risk Score for Prediction of 10-Year Atrial Fibrillation: A Community-Based Study

Doron Aronson
1   Department of Cardiology, Rambam Medical Center, Haifa, Israel
2   Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel
,
Varda Shalev
3   Maccabi Healthcare Services, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Rachel Katz
3   Maccabi Healthcare Services, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Gabriel Chodick
3   Maccabi Healthcare Services, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Diab Mutlak
1   Department of Cardiology, Rambam Medical Center, Haifa, Israel
2   Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel
› Institutsangaben
Weitere Informationen

Publikationsverlauf

30. April 2018

05. Juli 2018

Publikationsdatum:
13. August 2018 (online)

   Lizenzen und Reprints

Abstract

Purpose We used a large real-world data from community settings to develop and validate a 10-year risk score for new-onset atrial fibrillation (AF) and calculate its net benefit performance.

Methods Multivariable Cox proportional hazards model was used to estimate effects of risk factors in the derivation cohort (n = 96,778) and to derive a risk equation. Measures of calibration and discrimination were calculated in the validation cohort (n = 48,404).

Results Cumulative AF incidence rates for both the derivation and validation cohorts were 5.8% at 10 years. The final models included the following variables: age, sex, body mass index, history of treated hypertension, systolic blood pressure ≥ 160 mm Hg, chronic lung disease, history of myocardial infarction, history of peripheral arterial disease, heart failure and history of an inflammatory disease. There was a 27-fold difference (1.0% vs. 27.2%) in AF risk between the lowest (–1) and the highest (9) sum score. The c-statistic was 0.743 (95% confidence interval [CI], 0.737–0.749) for the derivation cohort and 0.749 (95% CI, 0.741–0.759) in the validation cohort. The risk equation was well calibrated, with predicted risks closely matching observed risks. Decision curve analysis displayed consistent positive net benefit of using the AF risk score for decision thresholds between 1 and 25% 10-year AF risk.

Conclusion We provide a simple score for the prediction of 10-year risk for AF. The score can be used to select patients at highest risk for treatments of modifiable risk factors, monitoring for sub-clinical AF detection or for clinical trials of primary prevention of AF.

Keywords

atrial fibrillation - models - risk assessment

Supplementary Material

 

  • References

  • 1 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 2 Chugh SS, Havmoeller R, Narayanan K. , et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129 (08) 837-847
    CrossrefPubMedGoogle Scholar
  • 3 Miyasaka Y, Barnes ME, Gersh BJ. , et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114 (02) 119-125
    CrossrefPubMedGoogle Scholar
  • 4 Lip GY, Fauchier L, Freedman SB. , et al. Atrial fibrillation. Nat Rev Dis Primers 2016; 2: 16016
    CrossrefPubMedGoogle Scholar
  • 5 Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs Aging 2002; 19 (11) 819-846
    CrossrefPubMedGoogle Scholar
  • 6 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (08) 983-988
    CrossrefPubMedGoogle Scholar
  • 7 Schnabel RB, Rienstra M, Sullivan LM. , et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 2013; 15 (08) 843-849
    CrossrefPubMedGoogle Scholar
  • 8 Lin HJ, Wolf PA, Kelly-Hayes M. , et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27 (10) 1760-1764
    CrossrefPubMedGoogle Scholar
  • 9 Schnabel RB, Sullivan LM, Levy D. , et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373 (9665): 739-745
    CrossrefPubMedGoogle Scholar
  • 10 Chamberlain AM, Agarwal SK, Folsom AR. , et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011; 107 (01) 85-91
    CrossrefPubMedGoogle Scholar
  • 11 Alonso A, Krijthe BP, Aspelund T. , et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013; 2 (02) e000102
    PubMedGoogle Scholar
  • 12 Kolek MJ, Graves AJ, Xu M. , et al. Evaluation of a prediction model for the development of atrial fibrillation in a repository of electronic medical records. JAMA Cardiol 2016; 1 (09) 1007-1013
    CrossrefPubMedGoogle Scholar
  • 13 Goldstein BA, Navar AM, Pencina MJ. Risk prediction with electronic health records: the importance of model validation and clinical context. JAMA Cardiol 2016; 1 (09) 976-977
    CrossrefPubMedGoogle Scholar
  • 14 Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol 2011; 152 (03) 345-349
    CrossrefPubMedGoogle Scholar
  • 15 Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 2014; 64 (03) 501-507
    CrossrefPubMedGoogle Scholar
  • 16 Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 2003; 18 (12) 1143-1146
    PubMedGoogle Scholar
  • 17 Shalev V, Goldshtein I, Halpern Y, Chodick G. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings. Pharmacotherapy 2014; 34 (01) 1-8
    CrossrefPubMedGoogle Scholar
  • 18 Shalev V, Goldshtein I, Porath A, Weitzman D, Shemer J, Chodick G. Continuation of statin therapy and primary prevention of nonfatal cardiovascular events. Am J Cardiol 2012; 110 (12) 1779-1786
    CrossrefPubMedGoogle Scholar
  • 19 Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011; 30 (01) 22-38
    CrossrefPubMedGoogle Scholar
  • 20 Sullivan LM, Massaro JM, D'Agostino Sr RB. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23 (10) 1631-1660
    CrossrefPubMedGoogle Scholar
  • 21 Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004; 23 (05) 723-748
    CrossrefPubMedGoogle Scholar
  • 22 Royston P. Explained variation for survival models. Stata J 2006; 6: 83-96
    PubMedGoogle Scholar
  • 23 Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008; 8: 53
    CrossrefPubMedGoogle Scholar
  • 24 Leening MJ, Steyerberg EW, Van Calster B, D'Agostino Sr RB, Pencina MJ. Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective. Stat Med 2014; 33 (19) 3415-3418
    CrossrefPubMedGoogle Scholar
  • 25 Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015; 162 (01) 55-63
    CrossrefPubMedGoogle Scholar
  • 26 Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60 (22) 2263-2270
    CrossrefPubMedGoogle Scholar
  • 27 Schnabel RB, Larson MG, Yamamoto JF. , et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009; 104 (01) 92-96
    CrossrefPubMedGoogle Scholar
  • 28 Conen D, Ridker PM, Everett BM. , et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 2010; 31 (14) 1730-1736
    CrossrefPubMedGoogle Scholar
  • 29 Sartori M, Conti E, Favaretto E, Frascaro M, Legnani C, Palareti G. Thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. Eur J Vasc Endovasc Surg 2011; 42 (06) 817-823
    CrossrefPubMedGoogle Scholar
  • 30 Nylaende M, Kroese A, Stranden E. , et al. Prothrombotic activity is associated with the anatomical as well as the functional severity of peripheral arterial occlusive disease. Thromb Haemost 2006; 95 (04) 702-707
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 31 Aronson D, Roterman I, Yigla M. , et al. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Respir Crit Care Med 2006; 174 (06) 626-632
    CrossrefPubMedGoogle Scholar
  • 32 Johnson LS, Juhlin T, Engström G, Nilsson PM. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace 2014; 16 (02) 182-188
    CrossrefPubMedGoogle Scholar
  • 33 Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do?. Eur Heart J 2015; 36 (46) 3250-3257
    PubMedGoogle Scholar
  • 34 Mureddu GF, Agabiti N, Rizzello V. , et al; PREDICTOR Study Group. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail 2012; 14 (07) 718-729
    CrossrefPubMedGoogle Scholar
  • 35 Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005; 45 (01) 87-92
    CrossrefPubMedGoogle Scholar
  • 36 Rosenberg MA, Gottdiener JS, Heckbert SR, Mukamal KJ. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J 2012; 33 (07) 904-912
    CrossrefPubMedGoogle Scholar
  • 37 Tsang TSM, Gersh BJ, Appleton CP. , et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40 (09) 1636-1644
    CrossrefPubMedGoogle Scholar